Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (594)	10/30/2006 12:05:19 PM
From: dr.praveen	Read Replies (1) \| Respond to of 2274

Just posting for reference: 5-HT2c receptor agonist In October 2002, Biovitrum signed an agreement that gives GlaxoSmithKline the exclusive right to develop and commercialize Biovitrum’s existing collection of patented 5-HT2c receptor agonists for the treatment of obesity and other medical disorders. In the Nordic countries, Biovitrum retains the exclusive right to commercialization of products arising from the collaboration. Two clinical studies in patients performed by Biovitrum, demonstrate 5-HT2c agonists to be a relevant approach to obesity treatment. The collaboration is now focused on even more selective 5-HT2c compounds from the patent portfolio. These compounds are currently in lead optimization phase at GlaxoSmithKline. 5-HT6 receptor antagonist There is a great need for drugs with new effective mechanisms against obesity. 5-HT6 receptors, which are linked to the reward system in the brain, have been identified as a new mechanism for drugs for the treatment of obesity. Biovitrum has produced selective 5-HT6 receptor antagonists and shown that they reduce food intake and thereby lower body weight in animal studies employing both shorter and longer treatment periods. One candidate drug (BVT.74316) is currently in Clinical phase I. Leptin receptor agonist The project is based on stimulating the leptin receptor. Biovitrum has developed the first orally available compound that effectively can pass over the brain’s leptin transport system and spread directly into the brain. Functional studies in both in vitro and in vivo models point to a true effect on leptin related pathways with diminished appetite and reduced body weight as result. It has been known for some time that leptin plays a central role in regulating appetite and food intake, and the area has therefore attracted considerable research interest within the field of obesity. A drug candidate was selected in February 2006 and it is currently subject to toxicology studies.